Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR)
- PMID: 16082605
- DOI: 10.1007/s11239-005-1849-9
Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR)
Abstract
Background: Heparin-induced thrombocytopenia (HIT) can lead to catastrophic thromboembolic complications and requires treatment with an alternative, rapidly active anticoagulant, such as a direct thrombin inhibitor (DTI), either to prevent or treat these complications. Switching to oral warfarin after initial treatment with a DTI is necessary in most patients. Most references related to warfarin suggest that an increased risk for bleeding will occur with elevated international normalized ratios (INRs) > 4.6. In patients receiving argatroban, it is not uncommon to achieve an INR > 4 during this transition. Because the clinical outcomes in patients achieving an INR > 4 during combined argatroban/warfarin therapies for HIT are not well described, we evaluated the clinical outcomes of 111 patients with this phenomenon.
Methods: We identified patients from the prospective studies of argatroban anticoagulation, Argatroban-911 and Argatroban-915. Data collected from these studies included death from all causes, amputation, new thrombosis, major bleeding, INR values, argatroban doses, aPTT values, platelet counts, and duration of therapy.
Results: Patients were on argatroban monotherapy for a median of 2.8 (0.1-8.1) days, and on cotherapy for a median of 3.7 (0.9-12.8) days. The median platelet count was 70.9 (18-325) x 10(9)/L at the time of HIT diagnosis and increased to 94 (30-324) x 10(9)/L by the time warfarin was initiated. At a median argatroban dose of 1.4 (0.2-2.0) mcg/kg/min, the maximum INR ranged from 4.1 to 21.2 (median 6.4, n = 111) and the corresponding aPTT ranged from 48.1 to 105 (median 71, n = 93) seconds. After argatroban cessation, the first recorded INR within 4 to 24 hours ranged from 1.5 to 12.5 (median 2.9, n = 58). Adverse clinical outcomes occurred in 9 (8.1%) patients during cotherapy and in 12 (10.8%) patients after argatroban anticoagulation was discontinued. Adverse clinical outcomes included 7 cases of new thrombosis, 3 amputations, 12 deaths and 1 major bleed. Eleven of 12 (91.7%) patients died due to causes other than thrombosis, and most deaths (83%) occurred following cotherapy. Five (4.5%) patients developed new thrombosis during argatroban/warfarin cotherapy despite an INR > 4. In contrast only 1 (0.9%) patient experienced major bleeding.
Conclusion: In patients receiving argatroban/warfarin cotherapy and with an elevated INR > 4, the risk for thrombosis exceeds the risk of bleeding. Traditional paradigms concerning elevated INRs and warfarin may need to be redesigned for the patient population on cotherapy with direct thrombin inhibitors.Abbreviated Abstract. The clinical outcomes of 111 patients with INRs > 4 while on combined argatroban (dose < or = 2 mcg/kg/min) and warfarin were evaluated. Adverse clinical outcomes (7 new thrombosis, 3 amputations, 12 deaths and 1 major bleed) occurred in 21 patients. Eleven deaths were due to causes other than thrombosis. Five patients developed new thrombosis while only 1 had major bleeding. The risk for thrombosis exceeds the risk of bleeding in patients with HIT despite an INR > 4.
Similar articles
-
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.Drug Saf. 2009;32(3):203-18. doi: 10.2165/00002018-200932030-00003. Drug Saf. 2009. PMID: 19338378 Review.
-
Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.Clin Appl Thromb Hemost. 2005 Jul;11(3):279-87. doi: 10.1177/107602960501100306. Clin Appl Thromb Hemost. 2005. PMID: 16015413 Clinical Trial.
-
Heparin-induced thrombocytopenia from venous thromboembolism treatment.J Intern Med. 2005 Dec;258(6):563-72. doi: 10.1111/j.1365-2796.2005.01573.x. J Intern Med. 2005. PMID: 16313480
-
Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis.Ren Fail. 2006;28(7):537-9. doi: 10.1080/08860220600843813. Ren Fail. 2006. PMID: 17050234
-
Argatroban in the management of heparin-induced thrombocytopenia.Vasc Health Risk Manag. 2010 Sep 7;6:813-9. doi: 10.2147/vhrm.s3904. Vasc Health Risk Manag. 2010. PMID: 20859550 Free PMC article. Review.
Cited by
-
Beware of Warfarin-Induced Skin Necrosis in the Setting of Heparin-Induced Thrombocytopenia.Cureus. 2020 Jun 27;12(6):e8857. doi: 10.7759/cureus.8857. Cureus. 2020. PMID: 32754398 Free PMC article.
-
Diagnosis and management of heparin-induced thrombocytopenia.Hematol Oncol Clin North Am. 2013 Jun;27(3):541-63. doi: 10.1016/j.hoc.2013.02.001. Epub 2013 Apr 13. Hematol Oncol Clin North Am. 2013. PMID: 23714311 Free PMC article. Review.
-
Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.Drug Saf. 2009;32(3):203-18. doi: 10.2165/00002018-200932030-00003. Drug Saf. 2009. PMID: 19338378 Review.
-
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Chest. 2012. PMID: 22315270 Free PMC article. Review.
-
Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.Drugs Aging. 2007;24(6):489-99. doi: 10.2165/00002512-200724060-00005. Drugs Aging. 2007. PMID: 17571914 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical